These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 23966300)

  • 1. Epidermal EGFR controls cutaneous host defense and prevents inflammation.
    Lichtenberger BM; Gerber PA; Holcmann M; Buhren BA; Amberg N; Smolle V; Schrumpf H; Boelke E; Ansari P; Mackenzie C; Wollenberg A; Kislat A; Fischer JW; Röck K; Harder J; Schröder JM; Homey B; Sibilia M
    Sci Transl Med; 2013 Aug; 5(199):199ra111. PubMed ID: 23966300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy.
    Mascia F; Lam G; Keith C; Garber C; Steinberg SM; Kohn E; Yuspa SH
    Sci Transl Med; 2013 Aug; 5(199):199ra110. PubMed ID: 23966299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine regulation by epidermal growth factor receptor inhibitors and epidermal growth factor receptor inhibitor associated skin toxicity in cancer patients.
    Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Steffens M; Scholl C; Hichert V; Seufferlein T; Stingl JC
    Eur J Cancer; 2014 Jul; 50(11):1855-63. PubMed ID: 24857781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topical JAK inhibition ameliorates EGFR inhibitor-induced rash in rodents and humans.
    You Q; Chen L; Li S; Liu M; Tian M; Cheng Y; Xia L; Li W; Yao Y; Li Y; Zhou Y; Ma Y; Lv D; Zhao L; Wang H; Wu Z; Hu J; Ju J; Jia C; Xu N; Luo J; Zhang S
    Sci Transl Med; 2024 Jun; 16(752):eabq7074. PubMed ID: 38896602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib.
    Guttman-Yassky E; Mita A; De Jonge M; Matthews L; McCarthy S; Iwata KK; Verweij J; Rowinsky EK; Krueger JG
    Eur J Cancer; 2010 Jul; 46(11):2010-9. PubMed ID: 20621734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor/mitogen-activated kinase inhibitor treatment induces a distinct inflammatory hair follicle response that includes collapse of immune privilege.
    Rutkowski D; Scholey R; Davies J; Pye D; Blackhall F; Warren RB; Jimenez F; Griffiths CEM; Paus R
    Br J Dermatol; 2024 Oct; 191(5):791-804. PubMed ID: 38857906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR signaling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis.
    Zhang Z; Xiao C; Gibson AM; Bass SA; Khurana Hershey GK
    J Immunol; 2014 Feb; 192(3):859-66. PubMed ID: 24337738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenylbutyrate suppresses distinct skin reactions that are enhanced by blockade of epidermal growth factor receptor signaling.
    Chung YL; Pui NN
    J Dermatol Sci; 2011 Dec; 64(3):163-73. PubMed ID: 21924869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ERK1/2 regulates epidermal chemokine expression and skin inflammation.
    Pastore S; Mascia F; Mariotti F; Dattilo C; Mariani V; Girolomoni G
    J Immunol; 2005 Apr; 174(8):5047-56. PubMed ID: 15814736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-36γ drives skin toxicity induced by EGFR/MEK inhibition and commensal Cutibacterium acnes.
    Satoh TK; Mellett M; Meier-Schiesser B; Fenini G; Otsuka A; Beer HD; Rordorf T; Maul JT; Hafner J; Navarini AA; Contassot E; French LE
    J Clin Invest; 2020 Mar; 130(3):1417-1430. PubMed ID: 31805013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphatase Regulator NIPP1 Restrains Chemokine-Driven Skin Inflammation.
    Verbinnen I; Jonkhout M; Liakath-Ali K; Szekér K; Ferreira M; Boens S; Rouget R; Nikolic M; Schlenner S; Van Eynde A; Bollen M
    J Invest Dermatol; 2020 Aug; 140(8):1576-1588. PubMed ID: 31972250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR inhibitors switch keratinocytes from a proliferative to a differentiative phenotype affecting epidermal development and barrier function.
    Joly-Tonetti N; Ondet T; Monshouwer M; Stamatas GN
    BMC Cancer; 2021 Jan; 21(1):5. PubMed ID: 33402117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
    Wagner LI; Berg SR; Gandhi M; Hlubocky FJ; Webster K; Aneja M; Cella D; Lacouture ME
    Support Care Cancer; 2013 Apr; 21(4):1033-41. PubMed ID: 23128934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stress-induced production of chemokines by hair follicles regulates the trafficking of dendritic cells in skin.
    Nagao K; Kobayashi T; Moro K; Ohyama M; Adachi T; Kitashima DY; Ueha S; Horiuchi K; Tanizaki H; Kabashima K; Kubo A; Cho YH; Clausen BE; Matsushima K; Suematsu M; Furtado GC; Lira SA; Farber JM; Udey MC; Amagai M
    Nat Immunol; 2012 Jun; 13(8):744-52. PubMed ID: 22729248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superoxide Dismutase 3 Inhibits LL-37/KLK-5-Mediated Skin Inflammation through Modulation of EGFR and Associated Inflammatory Cascades.
    Agrahari G; Sah SK; Nguyen CT; Choi SS; Kim HY; Kim TY
    J Invest Dermatol; 2020 Mar; 140(3):656-665.e8. PubMed ID: 31465746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventive effect of Diallyl Trisulfide on cutaneous toxicities induced by EGFR inhibitor.
    Liu Y; Jiang X; Gu Y; Chen Y
    Int Immunopharmacol; 2019 Apr; 69():79-87. PubMed ID: 30682720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.
    Kikuchi K; Nozawa K; Yamazaki N; Nakai Y; Higashiyama A; Asano M; Fujiwara Y; Kanda S; Ohe Y; Takashima A; Boku N; Inoue A; Takahashi M; Mori T; Taguchi O; Inoue Y; Mizutani H
    J Dermatol; 2019 Jan; 46(1):18-25. PubMed ID: 30402978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GPCR-mediated EGFR transactivation ameliorates skin toxicities induced by afatinib.
    Chen LY; You Q; Lv DZ; Li SH; Zhang SY
    Acta Pharmacol Sin; 2022 Jun; 43(6):1534-1543. PubMed ID: 34552215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MyD88-Dependent Signaling Decreases the Antitumor Efficacy of Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells.
    Koch AT; Love-Homan L; Espinosa-Cotton M; Stanam A; Simons AL
    Cancer Res; 2015 Apr; 75(8):1657-67. PubMed ID: 25712126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role for the epidermal growth factor receptor in chemotherapy-induced alopecia.
    Bichsel KJ; Gogia N; Malouff T; Pena Z; Forney E; Hammiller B; Watson P; Hansen LA
    PLoS One; 2013; 8(7):e69368. PubMed ID: 23894460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.